

Orserdu (elacestrant) Prior Authorization Request Form



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

MEMBER INFORMATION		
LAST NAME:	FIRST NAME:	
PHONE NUMBER:	DATE OF BIRTH:	
STREET ADDRESS:		
CITY:	STATE: ZIP CODE:	
PATIENT INSURANCE ID NUMBER:		

IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: <u>HTTPS://MAGELLANRX.COM/MEMBER/EXTERNAL/COMMERCIAL/COMMON/DOC/EN-US/PHI_DISCLOSURE_AUTHORIZATION.PDF</u>

MALE FEMALE HEIGHT (IN/CM): _____ WEIGHT (LB/KG): _____ ALLERGIES: _____

PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE): ______

AUTHORIZED REPRESENTATIVE'S PHONE NUMBER: _____

PRESCRIBER INFORMATION				
LAST NAME:	FIRST NAME:			
PRESCRIBER SPECIALTY:	EMAIL ADDRESS:			
NPI NUMBER:	DEA NUMBER:			
PHONE NUMBER:	FAX NUMBER:			
STREET ADDRESS:				
CITY:	STATE: ZIP CODE:			
REQUESTOR (if different than prescriber):	OFFICE CONTACT PERSON:			

MEDICATION OR MEDICAL DISPENSING INFORMATION					
MEDICATION NAME:					
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:		
NEW THERAPY	RENEWAL	IF RENEWAL: DATE THERAPY INITIATED:			
DURATION OF THERAPY (SPECIFIC DATES):					

Continued on next page.







Orserdu (elacestrant) Prior Authorization Request Form



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:				
1. HAS THE PATIENT TRIED ANY OTHE	R MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) 🗌 NO			
MEDICATION/THERAPY (SPECIFY	DURATION OF THERAPY (SPECIFY	RESPONSE/REASON FOR			
DRUG NAME AND DOSAGE):	DATES):	FAILURE/ALLERGY:			
2. LIST DIAGNOSES:		ICD-10:			
□ Locally advanced breast cancer					
 Metastatic breast cancer Other diagnosis: 	ICD-10:				
	I: PLEASE PROVIDE ALL RELEVANT CLIN	ICAL INFORMATION TO SUPPORT A			
PRIOR AUTHORIZATION.					
Clinical Information:					
Will drug be used as part of a clinical	trial? 🗆 Yes 🗆 No				
For FEMALE potients only is the pati	ant nactmononaucal2 - Vac - No				
For FEMALE patients only: Is the patients					
	tor (ER)-positive, human epidermal grov	wth factor receptor 2 (HER2)-negative			
disease (ER+/HER2-tumor status)?	Yes 🗆 No				
Does the patient have ESR-1 mutation positive disease? \square Yes \square No					
Has the patient previously received a	t least one and no more than two line	s of endocrine therapy for			
advanced/metastatic breast cancer?	🗆 Yes 🗆 No				
Has the patient received prior treatment with a CDK4/6 inhibitor in combination with either fulvestrant or an					
aromatase inhibitor (AI)? Yes No					
Has the patient had previous treatment with Orserdu (Elacestrant) bazedoxifene, or other investigational SERD or					
investigational ER antagonist? Yes No					
Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the					
physician feels is important to this review?					
Please note: Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required information is received.					
ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that					
the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical					
information necessary to verify the accuracy of the information reported on this form.					
Prescriber Signature or Electronic I.D. Verification: Date: Date:					
-					
© 2017–2023 by Magellan Rx Management, LLC	. All Rights Reserved.				

Revision Date: 08/01/2023 CAT0202



Magella



Orserdu (elacestrant) Prior Authorization Request Form



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

CONFIDENTIALITY NOTICE: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Magellan Rx Management Prior Authorization Program

Attn: CP – 4201 P.O. Box 64811 St. Paul, MN 55164-0811



